Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Biopharm Knowledge Publishing | Quality for Biologics

Quality for Biologics

Biologic drugs are complicated biological products that are normally difficult to define in molecular terms and that can be inconsistent in their exact composition. This can make it difficult to assure product quality and therefore to ensure safety and efficacy. There is no perfect solution and the commercial cost of quality is high, but the cost of getting it wrong can be considerably greater or even disastrous. Considerable time and expense can be saved by having an educated approach to manufacturing and process development, characterisation and analytical methods, product variation and also to regulatory issues. This unique new report provides a detailed and complete guide to the processes and methods involved.

Quality for Biologics is produced and edited by Dr Nicole Lyscom and is written by top industry experts from leading companies and organisations including:

* Genentech

* Amgen

* Roche

* Eli Lilly

* UCB

* LFB

* Boehringer Ingelheim

* Paul Ehrlich Institute

* Parexel Consulting

The report covers all aspects of the subject including

* Critical quality attributes

* Manufacturing process parameters

* Process Analytical Technology

* Physicochemical analysis

* Bioassays

* Formulation and specifications

* Product- and process-related impurities

* Aggregation

* Non-clinical testing

* Clinical development,

* Post-marketing quality control

* Regulatory authority expectations

* Risk management

* Comparability concerns

Quality for Biologics is essential reading for corporate management and those in product, process and analytical development, product quality and characterisation, R&D, and regulatory affairs. It is aimed at biotech, big pharma, producers of biosimilars / biogenerics / follow-on biologics, contract manufacturers, providers of analytical services, providers of manufacturing and analytical equipment, regulatory agencies and clinical research organizations. This case-study rich report gives an authoritative, detailed and clear explanation of the issues surrounding quality for biologics, its implications for the market and for the biotech and pharmaceutical industries.
Table of Contents
Report Synopsis
Price: $2,300.00 / €1,523.29

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions